<DOC>
	<DOCNO>NCT00436761</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor umbilical cord blood stem cell transplant help stop growth tumor cell . It also help stop patient 's immune system reject donor 's stem cell exactly match patient 's blood . The donated stem cell may replace patient 's immune cell help destroy remain tumor cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine methylprednisolone transplant may stop happen . PURPOSE : This phase I trial study side effect busulfan , melphalan , antithymocyte globulin follow umbilical cord blood transplant treat young patient refractory relapse malignant solid tumor .</brief_summary>
	<brief_title>Busulfan , Melphalan , Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant Treating Young Patients With Refractory Relapsed Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Examine impact use killer cell immunoglobulin-like receptor ( KIR ) -mismatched umbilical cord blood source hematopoietic stem cell , busulfan , melphalan , anti-thymocyte globulin pediatric patient relapse refractory solid tumor . - Determine toxicity regimen , term incidence grade 3-4 acute graft-versus-host disease , donor/host chimerism , cellular immunity tumor cell line , patient . OUTLINE : - Transplantation : Patients receive busulfan orally IV every 6 hour day -8 -5 , anti-thymocyte globulin IV 6 hour day -4 -1 , melphalan IV 15-20 minute day -4 -2 . Patients undergo allogeneic umbilical cord blood stem cell infusion day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously begin day 7 continue blood count recover . - Graft-vs-host disease prophylaxis : Patients receive cyclosporine IV 1 hour orally twice daily day -1 180 methylprednisolone IV orally twice daily day 5 - 49 . Blood sample collect periodically immunophenotyping flow cytometric analysis ( include interferon gamma TH1 TH2 cytokine ) . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignant solid tumor Relapsed refractory disease No isolate local recurrence disease ( site primary tumor ) &gt; 1 year complete therapy No brain tumor brain metastasis Unrelated cord blood donor available May HLA 6/6 match ( HLAA , B , DR ) OR mismatch 1 , 2 , 3 HLA locus , must mismatch HLAC group indicate follow killer cell immunoglobulinlike receptor ( KIR ) group specificity : KIR2DL1 Cw 2 Cw 0307 Cw 4 , 5 , 6 Cw 0707 , 0709 Cw 1204 , 1205 All Cw 15 allele Cw 1602 Cw 17 Cw 18 KIR2DL2 Cw 1 All Cw 3 allele All Cw 7 allele Cw 8 Cw 1202 , 1203 , 1206 Cw 1301 Cw 1402 , 1403 Cw 1507 Cw 1601 , 1604 Cord blood specimen must ≥ 1 x 10^7 nucleated cells/kg patient ideal body weight PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Lansky PS 70100 % Cardiac ejection fraction ≥ 50 % Creatinine clearance ≥ 50 % Bilirubin ≤ 3.0 mg/dL DLCO ≥ 70 % OR O_2 saturation ≥ 95 % room air PRIOR CONCURRENT THERAPY : Prior autologous stem cell transplantation allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>